WO2009095933A3 - Improved and novel process for the preparation of bosentan - Google Patents

Improved and novel process for the preparation of bosentan Download PDF

Info

Publication number
WO2009095933A3
WO2009095933A3 PCT/IN2009/000032 IN2009000032W WO2009095933A3 WO 2009095933 A3 WO2009095933 A3 WO 2009095933A3 IN 2009000032 W IN2009000032 W IN 2009000032W WO 2009095933 A3 WO2009095933 A3 WO 2009095933A3
Authority
WO
WIPO (PCT)
Prior art keywords
bosentan
preparation
improved
novel process
relates
Prior art date
Application number
PCT/IN2009/000032
Other languages
French (fr)
Other versions
WO2009095933A2 (en
Inventor
Manne Satyanarayana Reddy
Sajja Eswaraiah
Ghojala Venkat Reddy
Original Assignee
Msn Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msn Laboratories Limited filed Critical Msn Laboratories Limited
Priority to EP09705099A priority Critical patent/EP2240470A4/en
Publication of WO2009095933A2 publication Critical patent/WO2009095933A2/en
Publication of WO2009095933A3 publication Critical patent/WO2009095933A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

Abstract

The present invention relates to an improved and novel process for the preparation of bosentan compound of formula (1). The present invention also relates to a crystalline form of bosentan and its intermediates.
PCT/IN2009/000032 2008-01-10 2009-01-09 Improved and novel process for the preparation of bosentan WO2009095933A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09705099A EP2240470A4 (en) 2008-01-10 2009-01-09 Improved and novel process for the preparation of bosentan

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN103/CHE/2008 2008-01-10
IN103CH2008 2008-01-10
IN2334/CHE/2008 2008-09-24
IN2334CH2008 2008-09-24

Publications (2)

Publication Number Publication Date
WO2009095933A2 WO2009095933A2 (en) 2009-08-06
WO2009095933A3 true WO2009095933A3 (en) 2011-06-30

Family

ID=40913375

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000032 WO2009095933A2 (en) 2008-01-10 2009-01-09 Improved and novel process for the preparation of bosentan

Country Status (2)

Country Link
EP (1) EP2240470A4 (en)
WO (1) WO2009095933A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600010A (en) 2007-10-24 2013-11-29 Generics Uk Ltd Novel crystalline forms of bosentan, processes for their preparation and uses thereof
WO2009093127A2 (en) * 2008-01-24 2009-07-30 Actavis Group Ptc Ehf Substantially pure and a stable crystalline form of bosentan
WO2009098517A1 (en) 2008-02-08 2009-08-13 Generics [Uk] Limited Process for preparing bosentan
WO2010015623A1 (en) * 2008-08-05 2010-02-11 Farmaprojects, S. A. Process for the preparation of endothelin receptor antagonists
US20110263623A1 (en) * 2008-08-12 2011-10-27 Cadila Healthcare Limited Process for preparation of bosentan
EP2350028A1 (en) * 2008-11-03 2011-08-03 Generics [UK] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
IT1393136B1 (en) * 2009-03-11 2012-04-11 Sifa Vitor S R L PROCEDURE FOR THE PREPARATION OF BOSENTAN
MX2011010817A (en) 2009-04-13 2012-01-27 Sandoz Ag Process for preparation of endothelial receptor antagonist (bosentan).
WO2011021216A2 (en) * 2009-08-10 2011-02-24 Msn Laboratories Limited Improved process for the preparation of 4-(1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide
WO2011024056A2 (en) 2009-08-27 2011-03-03 Aurobindo Pharma Limited An improved process for the preparation of bosentan
WO2011058524A2 (en) * 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Crystalline forms of bosentan salt and processes for their preparation
EP2603497B1 (en) 2010-08-11 2018-08-08 Megafine Pharma (P) Ltd. A novel process for preparation of bosentan
TR201903012T4 (en) * 2010-10-01 2019-03-21 Zach System Spa Process for the preparation of bosentan monohydrate and its intermediates.
US20130245259A1 (en) 2012-03-16 2013-09-19 Natco Pharma Limited Process for the preparation of bosentan monohydrate
JP2015521594A (en) * 2012-06-12 2015-07-30 カディラ ファーマシューティカルズ リミテッド Method for producing bosentan
TR202018841A2 (en) * 2020-11-23 2021-01-21 Yilmaz Usta Duygu FORMULATION OF BOSENTAN MONOHYDRATE LOADED SELF-NANOEMULSIFIED DRUG CARRIER SYSTEMS (SNEDDS) PREPARED WITH LONG-CHAIN MONO AND DIGLYCERIDE MIXTURES

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292740A (en) * 1991-06-13 1994-03-08 Hoffmann-La Roche Inc. Sulfonamides
EP0601386A1 (en) * 1992-12-10 1994-06-15 F. Hoffmann-La Roche Ag Sulphonamides
WO2001081335A1 (en) * 2000-04-20 2001-11-01 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292740A (en) * 1991-06-13 1994-03-08 Hoffmann-La Roche Inc. Sulfonamides
EP0601386A1 (en) * 1992-12-10 1994-06-15 F. Hoffmann-La Roche Ag Sulphonamides
WO2001081335A1 (en) * 2000-04-20 2001-11-01 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOLLI, M.,H. ET AL.: "The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists", BIOORG. MED. CHEM. LETT., vol. 13, 2003, pages 955 - 959, XP002587197 *
See also references of EP2240470A2 *

Also Published As

Publication number Publication date
EP2240470A2 (en) 2010-10-20
WO2009095933A2 (en) 2009-08-06
EP2240470A4 (en) 2012-05-23

Similar Documents

Publication Publication Date Title
WO2009095933A3 (en) Improved and novel process for the preparation of bosentan
NZ600119A (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
WO2010014666A3 (en) Processes and intermediates for making sweet taste enhancers
WO2008089984A3 (en) Process for the preparation of ezetimibe and derivatives thereof
SG170729A1 (en) Processes and intermediates for preparing steric compounds
WO2011015522A3 (en) Process for the manufacture of pharmaceutically active compounds
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
WO2008062478A3 (en) Improved process for pure montelukast sodium through pure intermediates as well as novel amine salts
WO2008155615A3 (en) An improved process for the preparation of cephalosporin antibiotic
WO2008096372A3 (en) Process for preparing highly pure ezetimibe using novel intermediates
WO2010036329A3 (en) Process for making quinolone compounds
WO2010004578A3 (en) Novel and improved processes for the preparation of paliperidone
MY150280A (en) Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
EP2865678A3 (en) Crystalline hemi-tartrate form of a benzoimidazol-2-yl pyrimidine derivative
WO2011015287A3 (en) Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
WO2010011748A3 (en) Synthetic intermediates and processes
WO2010148063A3 (en) Cyclohexene 1,4-carboxylates
WO2009116081A3 (en) An improved process for the preparation of aprepitant
MX2010009926A (en) New process for the preparatiion of cyclohexanecarboxylic acid dericatives.
WO2011058524A3 (en) Crystalline forms of bosentan salts and processes for their preparation
UA102816C2 (en) Process for obtaining the crystalline form v of agomelatine
WO2007143014A3 (en) Methods for preparing glutamic acid derivatives and intermediates thereof
IL206570A0 (en) Trisubstituted 3,4-dihydro-1h-isoquinolin compound, process for its preparation, and its use
WO2010021000A3 (en) A process for the preparation of strontium ranelate
WO2008007391A3 (en) An improved process for the preparation of valsartan

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09705099

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009705099

Country of ref document: EP